When not to treat depression in PCOS with antidepressants

Vol. 4, No. 2 / February 2005

When not to treat depression in PCOS with antidepressants

Other medications may help women with hormone dysregulation and insulin resistance.

Natalie Rasgon, MD, PhD
Associate professor
Departments of psychiatry and behavioral sciences and obstetrics and gynecology
Stanford School of Medicine, Stanford, CA

Shana Elman, MA
Research assistant
Medical College of Wisconsin, Milwaukee

Women with depression and polycystic ovary syndrome (PCOS) can be trapped in a vicious cycle of hormonal dysregulation. Treating these patients appropriately—with or without antidepressants—requires an understanding of their underlying metabolic disorder.

This article presents a case1 that exemplifies the association between depression and PCOS (Box 1).2-4 Based on our research and clinical experience, we offer recommendations to help you manage depression in patients with PCOS.

Chronic depression with amenorrhea
Ms. K, age 30, presented for psychiatric evaluation of treatment-resistant recurrent major depression. Her symptoms included sad mood, sleep disturbance, decreased energy, anhedonia, poor concentration, and feelings of guilt and worthlessness. Her score of 28 on the Hamilton Rating Scale for Depression (HAM-D-21) indicated severe depression.

This was Ms. K’s third episode of major depression, with the first two occurring at ages 24 and 26. She reported similar symptoms each time. Previous psychiatrists had tried a variety of antidepressants with no therapeutic benefit before she responded to citalopram, 40 mg/d, at age 27. With this selective serotonin reuptake inhibitor, her depressive symptoms resolved for >1 year, except for mild irritability and low mood the week before menses.

Her depressive symptoms returned, however, and her previous psychiatrist treated her for approximately 13 months with extended-release venlafaxine, 225 mg/d. When she remained depressed, she was referred to our clinic for evaluation. Based on her history, we could not determine whether she had become euthymic at age 27 or her symptoms had improved but still met criteria for a major depressive episode.

Ms. K reported having PCOS symptoms from age 19. These included amenorrhea since menarche, hirsutism, hair loss, alopecia, central fat distribution characteristic of PCOS, and male-pattern hair growth on her abdomen and thighs. She was not obese—with a body mass index (BMI) of approximately 25—but had gained 10 to 15 lbs while taking venlafaxine.

Ms. K had never been treated for PCOS but reported that her desire to become pregnant made her more concerned about her symptoms and possible infertility.

Diagnosis. PCOS is usually diagnosed using endocrinologic, clinical, and ultrasonographic criteria (Table 1). Obesity is not a presenting symptom in all women with PCOS. As with Ms. K, about 50% of patients have normal BMI.

Causes of depression in PCOS. Depressed mood in PCOS may be both physiologic and psychological:

• Hypothalamic, pituitary, and other end-organ system dysregulation occurs in both PCOS and affective disorders, which share clinical and biochemical markers including insulin resistance, obesity, and hyperandrogenism.
• PCOS’ clinical sequelae—hirsutism, acne, obesity, hormonal disturbances, fear of infertility, and psychological distress—may damage their self-esteem and female identity.

PCOS’ physical symptoms alone apparently do not account for patients’ worsened mood states. Weiner et al5 found that women with PCOS and free testosterone (FT) of 10 to 26 pg/mL (just above normal range) were more depressed than women without PCOS (FT <10 pg/mL) and women with PCOS and FT >26 pg/mL. Women with PCOS with the lower and higher FT levels had similar demographic profiles, but those with the highest FT levels were not the most depressed.

Similarly, in a study of 32 women with PCOS, we found no association between depression and other possibly distressing PCOS symptoms, including hirsutism, irregular menses, acne, or alopecia.4

Testosterone and mood disorders. Women such as Ms. K with hyperandrogenic syndromes are at increased risk for mood disorders.6 Many metabolic changes associated with PCOS—insulin resistance, obesity, and hyperandrogenism—are also described in patients with affective disorders. Our investigation of reproductive status in women with bipolar disorder found no clinical or biochemical evidence of PCOS with mood-stabilizer treatment. We did find that menstrual disturbances were common, however, and sometimes preceded bipolar disorder onset.7

Insulin resistance and depression. Others have linked insulin resistance and depression;8 depression has been shown to be associated with impaired insulin sensitivity and hyperinsulinemia.9 Depressed persons also tend to eat more sweets, drink more alcohol, exercise less, and sleep fewer hours than the nondepressed—all of which contribute to insulin sensitivity and insulin resistance.10

What links endocrine, mood disorders?
Insulin and serotonin. Insulin affects central serotonin (5-HT) levels.11 Thus, central 5-HT system dysregulation that causes depression might also affect peripheral insulin sensitivity—or vice versa.9

Tryptophan, a serotonin precursor, competes with other large neutral amino acids for access to the transport system that moves them across the blood-brain barrier. Insulin stimulates uptake of the competing amino acids—but not tryptophan—into muscle tissue. The resulting increased tryptophan ratio in plasma affords it greater access to the transport system to contribute toward serotonin synthesis. Insulin also promotes central catecholaminergic activity, perhaps by suppressing norepinephrine reuptake and prolonging its residence in the synaptic cleft.10

Several studies have found that insulin resistance and hyperinsulinemia can resolve after depression recovery.9,12 Because insulin resistance is a cardinal feature in PCOS pathophysiology,2 insulin resistance may be a common link between depression and PCOS.

Weight gain and obesity also have been described in patients with affective disorders.13 Not known is whether the weight gain precedes the psychopathology or is caused by long-term exposure to drugs used to treat affective disorders.

We reported a correlation between depression and BMI in women with PCOS.4 Depression might be independently associated with BMI, as weight gain and obesity are distressing symptoms associated with depression.14 However, we found no association between depression and other possibly distressing PCOS symptoms. Thus, the correlation between BMI and depression might more likely reflect the relationship between depression and insulin resistance, as degree of insulin resistance is known to correlate with BMI.

Elevated cortisol. Clearly, other factors—such as hypothalamus-pituitary-adrenal (HPA) axis dysfunction—are known to link affective and endocrine disorders. Hypercortisolemia can lead to both insulin resistance and obesity. Cortisol is one of the glucocorticoids the body secretes in response to stress to mobilize energy by increasing blood glucose levels. Early life stress and chronic emotional stress:

• can impair the negative feedback system that limits cortisol production during stress
• are associated with depression.

Approximately one-half of individuals with depression have elevated serum cortisol.10 Epidemiologic data show a positive correlation between cortisol levels and insulin resistance,15 and an association between HPA dysfunction and obesity has been described.16 Insulin can trigger androgen production by enhancing adrenal sensitivity to adrenocorticotrophic hormone (ACTH).17

Case: Improving insulin resistance
We referred Ms. K to an endocrinologist for PCOS evaluation and treatment. Her serum glucose and insulin levels were 83 mg/dL (normal range 70 to 125 mg/dL) and 19.0 uIU/mL (normal range <10 uIU/mL), respectively. These values indicated insulin resistance as determined by the homeostasis model assessment (HOMA) ratio (fasting insulin times fasting glucose divided by 22.5). Values >3.2 indicate insulin resistance, and Ms. K had a HOMA ratio of 3.9. The endocrinologist recommended:

• metformin, starting at 850 mg/d and gradually increased to 2,550 mg/d
• spironolactone, 100 mg/d.

Metformin, a biguanide approved for treating for type 2 diabetes, inhibits hepatic glucose production and increases peripheral insulin sensitivity, but it does not modify pancreatic insulin secretion. It may decrease insulin resistance by reducing gut absorption of glucose, improving glucose uptake by tissues, and/or increasing the number of insulin receptors.18 In treating PCOS, metformin can:

• restore ovulation19
• decrease insulin resistance, acne, hirsutism, total and bioavailable estosterone, BMI, and waist-hip ratio.20,21

Although the link between insulin resistance and depression is unclear, insulin is known to contribute to 5-HT synthesis by promoting tryptophan influx into the brain.22 Therefore, drugs used to treat insulin resistance—such as metformin and alpha lipoic acid23 —might be useful in treating depression.

Spironolactone, a mineralocorticoid receptor (MR) antagonist, reduces hirsutism in women with PCOS.24 It also can decrease insulin resistance and fasting insulin levels in PCOS patients and reduce serum testosterone.25

Evidence on treating mood disorders with hormonal agents such as spironolactone is scarce, although treatment-resistant depression has been reported to resolve with antiglucocorticoid use (Box 2).25-31 Modulating HPA axis activity to treat affective disorders has been investigated.

Case: Going antidepressant-free
At first, Ms. K said she wanted to continue taking venlafaxine with the PCOS treatment. After 2 weeks of combined therapy, however, she chose to stop the antidepressant after her depressive symptoms persisted, and her HAM-D-21 score remained at 28.

During the next 4 weeks, as we tapered off the venlafaxine, Ms. K’s HAM-D-21 score dropped to 7, indicating depressive symptom resolution. Despite slow venlafaxine titration, withdrawal symptoms of excessive crying, not feeling “present,” and tingling sensations occurred. Three days of fluoxetine, 20 mg/d, alleviated these symptoms.

We continued Ms. K’s treatment without antidepressants, and her mood continued to improve with metformin, 2,550 mg/d, and spironolactone, 100 mg/d.

Treatment recommendations
PCOS therapy may take up to 6 months to resolve symptoms such as anovulation or hirsutism, but affective symptoms may improve during the first 6 weeks, as this case shows. Choosing medications to treat depression in patients such as Ms. K depends on whether their PCOS is being treated when they present for psychiatric evaluation.

Patient not being treated for PCOS. Refer her to an endocrinologist for PCOS treatment with an insulin-sensitizing medication, such as metformin (Table 2). Treating the insulin resistance associated with PCOS may also resolve the depression. PCOS drug therapy may also include antiandrogens such as spironolactone to treat hirsutism, male-pattern baldness, and acne. We suggest that spironolactone’s antiandrogen effects may help reduce depressive symptoms.

If your patient is not taking an antidepressant at presentation, try PCOS treatment first. If depressive symptoms persist after 3 months, consider adding an antidepressant. If your patient is taking an antidepressant at presentation but continues to be depressed, offer two options:

• taper off the antidepressant while starting PCOS treatment
• continue the antidepressant while starting PCOS treatment

The first option allows you to try PCOS treatment alone. If the depression is caused by a common underlying pathophysiology—such as insulin resistance—treating PCOS alone may alleviate her depressive symptoms. Monitor for withdrawal symptoms, which may be minimized with a short-term SSRI, such as fluoxetine.

The second option may help patients who have responded to antidepressants in the past. Adjunctive PCOS treatment may “jump-start” the antidepressant response without withdrawal symptoms, but you will not be sure whether the antidepressant response was caused by PCOS therapy alone or the combination therapy.

Patient being treated for PCOS. Treat her with antidepressants, and consult with her endocrinologist to consider more-aggressive insulin-sensitizing medications, especially if she exhibits high levels of insulin resistance.

Other interventions that increase insulin sensitivity and improve glycemic control—such as improving dietary management and sleep habits, reducing alcohol consumption, and increasing physical activity—might have an antidepressant effect. Therefore, recommend these health practices to patients as adjuncts to drug therapies.

Case: Depression in remission
At the 3-month follow-up visit, Ms. K scored zero on the HAM-D-21 scale. With metformin treatment, she had lost approximately 10 lbs and resumed menstruating approximately every 33 days. She reported experiencing low mood, decreased energy, and irritability during the week before her periods, but these symptoms resolved with menses onset.

Serum glucose was within normal range at 89 mg/dL, and serum insulin was 15.0 uIU/Ml. Her HOMA ratio had dropped to 2.8 (below the 3.2 cut-off for insulin resistance).

Ms. K’s endocrinologist monitored her spironolactone and metformin therapy for approximately 1 year, when she became pregnant.

Discussion. PCOS treatment duration depends on the patient’s response and her goals for therapy. Whether or not she continues PCOS treatment, her primary care physician or endocrinologist should continue to monitor her for insulin resistance’s metabolic consequences, including increased risk of type 2 diabetes and cardiovascular disease.

References

1. Rasgon NL, Carter MS, Elman S, et al. Common treatment of polycystic ovarian syndrome and major depressive disorder: case report and review. Curr Drug Targets Immune Endocr Metabol Disord 2002;2(1):97-102.
2. Franks S. Polycystic ovary syndrome. N Engl J Med 1995;333(13): 853-61.
3. Zawadski JK, Dunaif A. Diagnostic criteria for polycystic ovary
syndrome: towards a rational approach. In: Dunaif A, Givens JR, Haseltine FP, Merriam GR (eds). Polycystic ovary syndrome. Oxford, UK: Blackwell Scientific, 1992:377-84.
4. Rasgon NL, Rao R, Elman S, et al. Depression in women with polycystic ovary syndrome: clinical and biochemical correlates. J Affect Disord 2003;74(3):299-304.
5. Weiner CL, Primeau M, Ehrmann DA. Androgens and mood dysfunction in women: Comparison of women with polycystic ovarian syndrome to healthy controls. Psychosom Med 2004;66:356-62.
6. Fava GA, Grandi S, Savron G, et al. Psychosomatic assessment of hirsute women. Psychother Psychosom 1989;51:96-100.
7. Rasgon NL, Altshuler LL, Gudeman D, et al. Medication status and PCO syndrome in women with bipolar disorder: a preliminary report. J Clin Psychiatry 2000;61:173-8.
8. Okamura F, Tashiro A, Utsumi A, et al. Insulin resistance in patients with depression and its changes in the clinical course of depression: a report on three cases using the minimal model analysis. Internal Med 1999;38(3):257-60.
9. Okamura F, Tashiro A, Utsumi A, et al. Insulin resistance in patients with depression and its changes during the clinical course of depression: minimal model analysis. Metabolism 2000;49(10):1255-60.
10. Rasgon NL, Altshuler LL, Birtan JA, et al. Menstrual abnormalities in women with bipolar disorder (presentation). San Francisco: American Psychiatric Association annual meeting, May 2003.
11. Figlewicz DP. Endocrine regulation of neurotransmitter transporters. Epilepsy Res 1999;37(3):203-10.
12. Nathan RS, Sachar EJ, Asnis GM, et al. Relative insulin insensitivity and cortisol secretion in depressed patients. Psychiatry Res 1981;4:291.
13. Elmslie JL, Silverstone TJ, Mann JI, Williams SM. Determinants of overweight and obesity in patients with bipolar disorder. J Clin Psychiatry 2000;61:179.
14. Istvan J, Zavela K, Weidner G. Body weight and psychological distress in NHANES I. Int J Obes Relat Metab Disord 1992;16(12):999-1003.
15. Andrews RC, Walker BR. Glucocorticoids and insulin resistance: old hormones, new targets. Clin Sci 1999;96(5):513.
16. Pasquali R, Biscotti D, Spinucci G, et al. Pulsatile secretion of ACTH and cortisol in premenopausal women: effect of obesity and body fat distribution. Clin Endocrinol 1998;48(5):603.
17. Moghetti P, Castello R, Negri C, et al. Insulin infusion amplifies 17 alpha-hydroxycorticosteroid intermediates response to adrenocorticotropin in hyperandrogenic women: apparent relative impairment of 17,20-lyase activity. J Clin Endocrinol Metabol 1996;81(3):881.
18. Bailey CJ, Day C, Bray GA, et al. Role of adrenal glands in the development of abnormal glucose and insulin homeostasis in genetically obese (ob/ob) mice. Horm Metab Res 1986;18(6):357.
19. Sills SE, Perloe M, Palermo GD. Correction of hyperinsulinemia in oligoovulatory women with clomiphene-resistant polycystic ovary syndrome: a review of therapeutic rationale and reproductive outcomes. Eur J Obstet Gynecol Reprod Biol 2000;91(2):135.
20. Nestler JE, Jakubowicz DJ, Evans WS, Pasquali R. Effects of metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome. N Engl J Med 1998;338(26):1876.
21. Velasquez EM, Mendoza S, Hamer T, et al. Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy. Metabolism 1994;43(5):647.
22. Chaouloff F. Effects of acute physical exercise on central serotonergic systems. Med Sci Sports Exerc 1997;29(1):58.
23. Salazar M. Alpha lipoic acid: a novel treatment for depression. Medical Hypoth 2000;55:510.
24. Spritzer PM, Lisboa KO, Mattiello S, Lhullier F. Spironolactone as a single agent for long-term therapy of hirsute patients. Clin Endocrinol 2000;52:587.
25. Moghetti P, Tosi F, Castello R, et al. The insulin resistance in women with hyperandrogenism is partially reversed by antiandrogen treatment: evidence that androgens impair insulin action in women. J Clin Endocrinol Metabol 1996;81(3):952.
26. Zobel AW, Nickel T, Kunzel HE. Effects of the high-affinity corticotropin-releasing hormone receptor 1 antagonist R121919 in major depression: the first 20 patients treated. J Psychiatric Res 2000;34:171.
27. Healy DG, Harkin A, Cryan JF, et al. Metyrapone displays antidepressant-like properties in preclinical paradigms. Psychopharmacol 1999;145(3):303.
28. Bech P, Raabaek Olsen L, Jarløv N, et al. A case of sequential anti-stress medication in a patient with major depression resistant to amine-reuptake inhibitors. Acta Psychiatr Scand 1999:100;76.
29. Wolkowitz OM, Reus VI, Chan T, et al. Antiglucocorticoid treatment of depression: double-blind ketoconazole. J Biol Psychiatry 1999;45(8):1070.
30. Murphy BE, Filipini D, Ghadirian AM. Possible use of glucocorticoid receptor antagonists in the treatment of major depression: preliminary results using RU 486. J Psychiatry Neurosci 1993;18(5):209.
31. Schatzberg AF, Rothschild AJ, Langlais PJ, et al. A corticosteroid/dopamine hypothesis for psychotic depression and related states. J Psychiatr Res 1985;19(1):57.

Related resources

Legro RS, Winans EA. Overview of polycystic ovary syndrome and its relation to psychiatric illness and treatment. Current Psychiatry 2004;3(Dec [suppl]):12-20.

The Rotterdam ESHRE/ASRM-sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004; 81(1):19-25.

Polycystic ovary syndrome (patient information). The National Women’s Health Information Center. U.S. Department of Health and Human Services, Office on Women’s Health. Available at: http://www.4woman.gov/faq/pcos.htm. Accessed Jan. 13, 2005.

Drug brand names

Citalopram • Celexa
Fluoxetine • Prozac
Ketoconazole • Nizoral
Metformin • Glucophage
Metyrapone • Metopirone
Mifepristone • Mifiprex
Pioglitazone • Actos
Rosiglitazone • Avandia
Spironolactone • Aldactone
Venlafaxine • Effexor XR

Disclosures

The authors report no financial relationship with any company whose products are mentioned in this article or with manufacturers of competing products.